X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TORRENT PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA TORRENT PHARMA GLENMARK PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 19.7 36.9 53.3% View Chart
P/BV x 3.5 5.7 61.2% View Chart
Dividend Yield % 0.3 0.9 36.2%  

Financials

 GLENMARK PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
TORRENT PHARMA
Mar-17
GLENMARK PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9931,768 56.2%   
Low Rs7291,186 61.5%   
Sales per share (Unadj.) Rs325.5346.1 94.1%  
Earnings per share (Unadj.) Rs39.355.2 71.2%  
Cash flow per share (Unadj.) Rs48.773.3 66.4%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.20.9 24.5%  
Book value per share (Unadj.) Rs159.2257.1 61.9%  
Shares outstanding (eoy) m282.17169.22 166.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.3 62.0%   
Avg P/E ratio x21.926.8 81.9%  
P/CF ratio (eoy) x17.720.1 87.8%  
Price / Book Value ratio x5.45.7 94.2%  
Dividend payout %5.125.4 20.1%   
Avg Mkt Cap Rs m242,991249,887 97.2%   
No. of employees `00013.011.8 110.1%   
Total wages/salary Rs m16,4089,934 165.2%   
Avg. sales/employee Rs Th7,083.94,971.5 142.5%   
Avg. wages/employee Rs Th1,265.4843.2 150.1%   
Avg. net profit/employee Rs Th855.1792.4 107.9%   
INCOME DATA
Net Sales Rs m91,85758,569 156.8%  
Other income Rs m3742,233 16.7%   
Total revenues Rs m92,23060,802 151.7%   
Gross profit Rs m20,36713,773 147.9%  
Depreciation Rs m2,6443,069 86.1%   
Interest Rs m2,3732,056 115.5%   
Profit before tax Rs m15,72410,881 144.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8271,545 247.7%   
Profit after tax Rs m11,0889,336 118.8%  
Gross profit margin %22.223.5 94.3%  
Effective tax rate %24.314.2 171.4%   
Net profit margin %12.115.9 75.7%  
BALANCE SHEET DATA
Current assets Rs m68,74653,841 127.7%   
Current liabilities Rs m27,02731,612 85.5%   
Net working cap to sales %45.438.0 119.7%  
Current ratio x2.51.7 149.3%  
Inventory Days Days8597 87.5%  
Debtors Days Days9684 114.0%  
Net fixed assets Rs m24,13242,079 57.3%   
Share capital Rs m282846 33.3%   
"Free" reserves Rs m44,64342,655 104.7%   
Net worth Rs m44,92543,501 103.3%   
Long term debt Rs m45,36322,408 202.4%   
Total assets Rs m117,639101,250 116.2%  
Interest coverage x7.66.3 121.2%   
Debt to equity ratio x1.00.5 196.0%  
Sales to assets ratio x0.80.6 135.0%   
Return on assets %11.411.3 101.7%  
Return on equity %24.721.5 115.0%  
Return on capital %19.119.6 97.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15220,066 279.8%   
Fx outflow Rs m8,0845,304 152.4%   
Net fx Rs m48,06814,762 325.6%   
CASH FLOW
From Operations Rs m6,57410,127 64.9%  
From Investments Rs m-7,124-7,869 90.5%  
From Financial Activity Rs m5,432-1,918 -283.2%  
Net Cashflow Rs m1,992212 942.0%  

Share Holding

Indian Promoters % 48.3 71.5 67.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 7.0 98.3%  
FIIs % 34.4 12.6 273.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   56,727 26,511 214.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 18, 2018 03:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS